Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (581-590 of 649) with videos related to

Pageof 65
Sort By:
Breast Cancer Research and Treatment|December 17, 2008
No evidence that GATA3 rs570613 SNP modifies breast cancer riskSharon E Johnatty, Fergus J Couch, Zachary Fredericksen, et al.
JAMA|June 21, 2017
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersKaroline B Kuchenbaecker, John L Hopper, Daniel R Barnes, et al.
NPJ Breast Cancer|May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variantsTaru A Muranen, Anna Morra, Sofia Khan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Breast Cancer Research : BCR|December 1, 2010
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriersLogan C Walker, Zachary S Fredericksen, Xianshu Wang, et al.
Human Molecular Genetics|March 25, 2016
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithmsMiguel de la Hoya, Omar Soukarieh, Irene López-Perolio, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 12, 2011
Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriersAmanda B Spurdle, Louise Marquart, Lesley McGuffog, et al.
Journal of Medical Genetics|May 14, 2026
Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languagesArcangela De Nicolo, Diana M Eccles, Kirsimari Aaltonen, et al.
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
Breast Cancer Research : BCR|November 13, 2016
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 womenTimothy R Rebbeck, Tara M Friebel, Nandita Mitra, et al.
Pageof 65

Showing results (581-590 of 649) with videos related to

Sort By:
Pageof 65
Breast Cancer Research and Treatment|December 17, 2008
No evidence that GATA3 rs570613 SNP modifies breast cancer riskSharon E Johnatty, Fergus J Couch, Zachary Fredericksen, et al.
JAMA|June 21, 2017
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersKaroline B Kuchenbaecker, John L Hopper, Daniel R Barnes, et al.
NPJ Breast Cancer|May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variantsTaru A Muranen, Anna Morra, Sofia Khan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Breast Cancer Research : BCR|December 1, 2010
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriersLogan C Walker, Zachary S Fredericksen, Xianshu Wang, et al.
Human Molecular Genetics|March 25, 2016
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithmsMiguel de la Hoya, Omar Soukarieh, Irene López-Perolio, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 12, 2011
Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriersAmanda B Spurdle, Louise Marquart, Lesley McGuffog, et al.
Journal of Medical Genetics|May 14, 2026
Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languagesArcangela De Nicolo, Diana M Eccles, Kirsimari Aaltonen, et al.
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
Breast Cancer Research : BCR|November 13, 2016
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 womenTimothy R Rebbeck, Tara M Friebel, Nandita Mitra, et al.
Pageof 65